Sarepta Therapeutics, Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by Robert W. Baird in a report released on Monday. They currently have a $101.00 price target on the biotechnology company’s stock. Robert W. Baird’s target price would suggest a potential upside of 105.37% from the stock’s current price.

A number of other analysts have also recently commented on SRPT. Janney Montgomery Scott boosted their price target on Sarepta Therapeutics from $65.00 to $73.00 and gave the stock a “fair value” rating in a research report on Monday, July 24th. Credit Suisse Group lifted their price objective on Sarepta Therapeutics from $5.65 to $81.00 and gave the company an “outperform” rating in a research note on Thursday, September 7th. Nomura reissued a “buy” rating and issued a $84.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, September 5th. Needham & Company LLC reissued a “buy” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Wednesday, September 6th. Finally, Zacks Investment Research cut Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fifteen have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $62.79.

Shares of Sarepta Therapeutics (SRPT) opened at 49.18 on Monday. Sarepta Therapeutics has a 52-week low of $26.26 and a 52-week high of $63.03. The company has a 50-day moving average price of $42.47 and a 200-day moving average price of $35.98. The stock’s market capitalization is $3.16 billion.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, July 19th. The biotechnology company reported ($0.46) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.92) by $0.46. The business had revenue of $35.01 million for the quarter, compared to the consensus estimate of $22.52 million. During the same period in the prior year, the business posted ($1.19) EPS. Sarepta Therapeutics’s revenue for the quarter was up 350000.0% on a year-over-year basis. On average, equities analysts anticipate that Sarepta Therapeutics will post ($1.22) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.watchlistnews.com/robert-w-baird-reiterates-outperform-rating-for-sarepta-therapeutics-inc-srpt/1606492.html.

In other Sarepta Therapeutics news, SVP Shamim Ruff sold 12,138 shares of the company’s stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $42.97, for a total transaction of $521,569.86. Following the completion of the sale, the senior vice president now directly owns 27,312 shares of the company’s stock, valued at $1,173,596.64. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Alexander Cumbo sold 5,918 shares of the company’s stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $41.00, for a total transaction of $242,638.00. Following the sale, the senior vice president now directly owns 22,793 shares of the company’s stock, valued at $934,513. The disclosure for this sale can be found here. In the last three months, insiders sold 78,056 shares of company stock worth $3,224,208. 9.60% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its stake in shares of Sarepta Therapeutics by 4,403.1% during the 1st quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock worth $156,664,000 after acquiring an additional 5,175,193 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Sarepta Therapeutics by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock valued at $143,572,000 after acquiring an additional 162,543 shares during the period. State Street Corp grew its position in shares of Sarepta Therapeutics by 21.2% during the 1st quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock valued at $94,641,000 after acquiring an additional 559,342 shares during the period. HealthCor Management L.P. grew its position in shares of Sarepta Therapeutics by 31.1% during the 2nd quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after acquiring an additional 481,890 shares during the period. Finally, Camber Capital Management LLC bought a new stake in shares of Sarepta Therapeutics during the 1st quarter valued at $39,960,000. Institutional investors and hedge funds own 65.41% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.